Close Menu

NEW YORK (GenomeWeb) – A group led by University of Pittsburgh Medical Center researchers has developed a next-generation sequencing assay that targets specific somatic mutations associated with late-stage breast cancer.

The assay, called MammaSeq NGS, comprehensively covers known driver hotspots targeting 79 genes and 1,369 mutations which the team believes could help cancer researchers identify clinically actionable mutations and potential therapeutic targets.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.